8 reports

The drug candidate binds to and inhibits the mRNA of Orai ##, inhibiting the calcium transport.

  • Antifungal
  • Eye Disease
  • Ophthalmology
  • Psychotic Disorder
  • Aldeyra Therapeutics, Inc.

Efficacy was evaluated at Night ## (first drug administration) and after ## weeks of drug administration (Night ##).

  • Ophthalmology
  • Psychotic Disorder
  • Therapy
  • United States
  • Eisai Co., Ltd.

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Antifungal
  • Monoclonal Antibody
  • Ophthalmology
  • Psychotic Disorder
  • SCYNEXIS, Inc.

Subjects orally took study drug once daily in the evening for one month.

  • Eye Disease
  • Ophthalmology
  • Psychotic Disorder
  • United States
  • Product Initiative

Subjects orally took study drug once daily in the evening for one month.

  • Eye Disease
  • Ophthalmology
  • Psychotic Disorder
  • United States
  • Product Initiative

(allergy and autoimmune diagnostics) which was sold to Thermo Fisher Scientific (TMO) in September of 2011.

  • Ophthalmology
  • Psychotic Disorder
  • Research And Development
  • United States
  • ProQR Therapeutics N.V.

CY-## - DRUG PROFILE DORA-## - DRUG PROFILE DRGT-## - DRUG PROFILE DRUG FOR INSOMNIA - DRUG PROFILE DRUGS TO INHIBIT ANGIOTENSIN II RECEPTOR TYPE ## FOR INSOMNIA - DRUG PROFILE EVT-## - DRUG PROFILE Drug Name C

  • Ophthalmology
  • Psychotic Disorder
  • Sleep Aid
  • United States
  • Product Initiative

The drug candidate is a ##-imino-##, ##, ##-thiadiazole derivative.

  • Ophthalmology
  • Pharmaceutical
  • Psychotic Disorder
  • United States
  • Product Initiative